These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Determinants of free serum valproate concentration: A prospective study in patients on divalproex sodium monotherapy. Nasreddine W; Dirani M; Atweh S; Makki A; Beydoun A Seizure; 2018 Jul; 59():24-27. PubMed ID: 29730272 [TBL] [Abstract][Full Text] [Related]
4. Safety range of free valproic acid serum concentration in adult patients. Tseng YJ; Huang SY; Kuo CH; Wang CY; Wang KC; Wu CC PLoS One; 2020; 15(9):e0238201. PubMed ID: 32877431 [TBL] [Abstract][Full Text] [Related]
5. Thrombocytopenia during intravenous valproic acid therapy in the neurological intensive care unit. Kim DW; Kim W; Lee CH; Chun YI J Clin Pharm Ther; 2020 Oct; 45(5):1014-1020. PubMed ID: 32040242 [TBL] [Abstract][Full Text] [Related]
7. Decreased platelet count in children with epilepsy treated with valproate and its relationship to the immature platelet fraction. Kurahashi H; Takami A; Murotani K; Numoto S; Okumura A Int J Hematol; 2018 Jan; 107(1):105-111. PubMed ID: 28879549 [TBL] [Abstract][Full Text] [Related]
8. Severe, isolated thrombocytopenia under polytherapy with carbamazepine and valproate. Finsterer J; Pelzl G; Hess B Psychiatry Clin Neurosci; 2001 Aug; 55(4):423-6. PubMed ID: 11442896 [TBL] [Abstract][Full Text] [Related]
9. Computerized tremor analysis of valproate-induced tremor: a comparative study of controlled-release versus conventional valproate. Rinnerthaler M; Luef G; Mueller J; Seppi K; Wissel J; Trinka E; Bauer G; Poewe W Epilepsia; 2005 Feb; 46(2):320-3. PubMed ID: 15679514 [TBL] [Abstract][Full Text] [Related]
10. Conversion from delayed-release sodium valproate to extended-release sodium valproate: initial results and long-term follow-up. McCabe PH; Michel NC; McNew CD; Lehman EB Epilepsy Behav; 2006 May; 8(3):601-5. PubMed ID: 16678766 [TBL] [Abstract][Full Text] [Related]
11. Valproate-associated coagulopathies are frequent and variable in children. Gerstner T; Teich M; Bell N; Longin E; Dempfle CE; Brand J; König S Epilepsia; 2006 Jul; 47(7):1136-43. PubMed ID: 16886976 [TBL] [Abstract][Full Text] [Related]
12. Valproate-mediated disturbances of hemostasis: relationship to dose and plasma concentration. Gidal B; Spencer N; Maly M; Pitterle M; Williams E; Collins M; Jones J Neurology; 1994 Aug; 44(8):1418-22. PubMed ID: 8058141 [TBL] [Abstract][Full Text] [Related]
13. Thrombocytopenia during valproic acid treatment in young patients with new-onset bipolar disorder. De Berardis D; Campanella D; Matera V; Gambi F; La Rovere R; Sepede G; Grimaldi MR; Pacilli AM; Salerno RM; Ferro FM J Clin Psychopharmacol; 2003 Oct; 23(5):451-8. PubMed ID: 14520121 [TBL] [Abstract][Full Text] [Related]
14. Prevalence and risk of thrombocytopenia with valproic acid: experience at a psychiatric teaching hospital. Conley EL; Coley KC; Pollock BG; Dapos SV; Maxwell R; Branch RA Pharmacotherapy; 2001 Nov; 21(11):1325-30. PubMed ID: 11714204 [TBL] [Abstract][Full Text] [Related]
15. Occurrence of thrombocytopenia in psychiatric patients taking valproate. Trannel TJ; Ahmed I; Goebert D Am J Psychiatry; 2001 Jan; 158(1):128-30. PubMed ID: 11136646 [TBL] [Abstract][Full Text] [Related]
18. Topiramate enhances the risk of valproate-associated side effects in three children. Longin E; Teich M; Koelfen W; König S Epilepsia; 2002 Apr; 43(4):451-4. PubMed ID: 11952778 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the metabolic syndrome risk in valproate-treated patients with epilepsy and the general population in Estonia. Rakitin A; Eglit T; Kõks S; Lember M; Haldre S PLoS One; 2014; 9(7):e103856. PubMed ID: 25078464 [TBL] [Abstract][Full Text] [Related]
20. Platelet count and function in children receiving sodium valproate. Verrotti A; Greco R; Matera V; Altobelli E; Morgese G; Chiarelli F Pediatr Neurol; 1999 Sep; 21(3):611-4. PubMed ID: 10513686 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]